Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Common Equity (2017 - 2025)

Historic Common Equity for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $105.2 million.

  • Innate Pharma's Common Equity fell 3551.7% to $105.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $105.2 million, marking a year-over-year decrease of 3551.7%. This contributed to the annual value of $120.2 million for FY2024, which is 3656.91% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Common Equity is $105.2 million, which was down 3551.7% from $118.7 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Common Equity ranged from a high of $320.6 million in Q2 2021 and a low of $105.2 million during Q2 2025
  • Its 5-year average for Common Equity is $214.5 million, with a median of $212.1 million in 2022.
  • As far as peak fluctuations go, Innate Pharma's Common Equity tumbled by 9990.37% in 2021, and later tumbled by 666.35% in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's Common Equity stood at $306.0 million in 2021, then tumbled by 30.7% to $212.1 million in 2022, then fell by 11.12% to $188.5 million in 2023, then tumbled by 37.04% to $118.7 million in 2024, then fell by 11.36% to $105.2 million in 2025.
  • Its Common Equity was $105.2 million in Q2 2025, compared to $118.7 million in Q4 2024 and $163.1 million in Q2 2024.